ArticleUnited European gastroenterology journal2018
Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis.
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Correlation Between Proton Pump Inhibitors and the Complications of Liver Cirrhosis: A Systematic Review and Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Pooled it
- Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis.Clinical drug investigation · 2019Pooled it
- Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis.World journal of gastroenterology · 2019Pooled it
- Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis.World journal of gastroenterology · 2019Pooled it
- Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks.Current gastroenterology reports · 2024Review
- Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2023Article
- Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study.Biomedicines · 2022Article
- Effect of a Proton Pump Inhibitor on the Duodenum Microbiome of Gastric Ulcer Patients.Life (Basel, Switzerland) · 2022Article
- Impact of proton pump inhibitors on the in-hospital outcome of COVID-19 patients: a retrospective study.Therapeutic advances in gastroenterology · 2022Article
- Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study.Journal of personalized medicine · 2021Article
- Characteristics of peptic ulcer bleeding in cirrhotic patients with esophageal and gastric varices.Scientific reports · 2020Article
- Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis.Journal of clinical medicine · 2019Article
- Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified.World journal of gastroenterology · 2019Review
- Vasoconstrictors in combination with proton pump inhibitors as an initial treatment of acute upper gastrointestinal bleeding in liver cirrhosis: is it evidence based?Annals of translational medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic encephalopathy is associated with altered gut microbiota. Proton pump inhibitors increase the risk of small bowel bacterial overgrowth.
objectivesThis was a case-control study aimed at exploring the relationship of proton pump inhibitor use with the risk of hepatic encephalopathy during hospitalization in liver cirrhosis.
methodsCase and control groups were defined as cirrhotic patients who developed hepatic encephalopathy during hospitalization and those without hepatic encephalopathy at admission or during hospitalization, respectively. Age, gender, and Child-Pugh score were matched between the groups. Odds ratios with 95% confidence intervals were calculated to express the association of proton pump inhibitors with the risk of hepatic encephalopathy. Four subgroup analyses were performed after excluding patients with acute upper gastrointestinal bleeding, infections, and in-hospital death, and after matching model for end-stage liver disease score.
resultsIn the overall analysis, 128 patients were included in each group of cases and controls. The proportion of proton pump inhibitor use was significantly higher in the case group than the control group (79.7% vs 43%,
conclusionProton pump inhibitor use might increase the risk of hepatic encephalopathy during hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.